Terrestrial Bio Series C Funding: $50M Secured

Terrestrial Bio Series C funding closed a $50 million round on March 26, 2026, according to the company's official press release. The Boston-based biotech, formerly Vaxess Technologies, disclosed that RA Capital led the round with participation from Engine Ventures, GHIC, and SiteGround, a move that also accompanies a strategic rebrand to Terrestrial Bio. The funding signals a pivotal step in Terrestrial Bio’s shift toward needle-free, self-administered therapeutic delivery and a broader plan to scale manufacturing and clinical development. This milestone was announced in a Boston press release dated March 26, 2026, and the company underscored that the new capital would support late-stage development, manufacturing expansion, and a new headquarters as it prepares for clinical trials of its lead GLP-1 program. The company’s leadership highlighted a renewed focus on accessibility and patient-centered delivery, a thematic throughline of the funding press release. .

The funding announcement arrives alongside Terrestrial Bio’s broader corporate evolution, including a lease agreement that cements its manufacturing footprint in Boston’s Allston neighborhood. The press release notes that Terrestrial Bio has signed a lease with King Street Properties for a manufacturing facility spanning more than 40,000 square feet, designed to support automated, scaled production of microarray patches for late-stage development and early commercialization. The move is framed as both a capacity expansion and a strategic relocation that aligns with the company’s plan to bring its GLP-1 program to the clinic and, eventually, the market. Rachel Sha, the company’s CEO, emphasized the mission of rethinking therapy delivery to reduce dependence on refrigeration and sharps while enabling self-administration at home or on the go. “In recent years, it became clear that our company name should more clearly reflect our focus on therapies and patient-centered delivery,” Sha remarked in the same release. The press release positions Terrestrial Bio’s MAP platform as a flexible delivery system designed for self-administration and broad therapeutic applicability, starting with GLP-1. [Terrestrial Bio press release is dated March 26, 2026 in Boston.]

Investors and the capital structure around this Series C round are also highlighted in the release. RA Capital Management led the round, with Engine Ventures, GHIC, and SiteGround contributing as co-investors. The collaboration underscores a diversified syndicate of biotech, growth-stage, and strategic investors backing Terrestrial Bio’s pivot toward a consumer-friendly delivery modality. In parallel with the financing news, RA Capital publicly acknowledged the milestone through its own channels, noting the strategic importance of Terrestrial Bio’s approach to GLP-1 delivery and the potential for near-term clinical progress. RA Capital’s public statements emphasize the strategic fit between the funding round and the company’s pathway to the clinic, while also signaling the broader investor confidence in tough-tech platforms that can reimagine how high-value biologics reach patients. .

What happened next is not simply a financial milestone; it marks a strategic inflection point for Terrestrial Bio’s product and market trajectory. The company’s leadership has framed the Series C as a launchpad for a manufacturing-scale transition and a more aggressive clinical development timetable. The lease and facility expansion—specifically, the Allston Labworks site—are positioned to support a more automated, scalable production line that could ultimately reduce costs per unit and shorten time-to-patient. This alignment of capital, real estate, and manufacturing capability is being framed as essential to meeting the demand for needle-free therapeutics, particularly GLP-1 therapies, which the press release notes have generated billions in global market sales in recent years. The combination of funding, rebranding, and facility expansion has positioned Terrestrial Bio to move beyond early-stage research into late-stage development and early commercial activity, with the company signaling readiness to execute a broader go-to-market strategy in the coming years.

Section 1: What Happened

Announcement Details

• The central event: Terrestrial Bio Series C funding totaling $50 million, announced March 26, 2026, in Boston. The round was led by RA Capital Management, with Engine Ventures, GHIC, and SiteGround participating as co-investors. This financing accompanies a corporate rebrand from Vaxess Technologies to Terrestrial Bio. Source: Terrestrial Bio press release dated March 26, 2026. The primary public-facing document, a company press release, confirms these exact figures and the leadership of the round. It also outlines the intended use of proceeds, including advancing the GLP-1 program and expanding manufacturing capacity. For readers seeking the original wording, see the Terrestrial Bio press release. >.

Investors and Governance

• Investor roster and leadership: RA Capital Management led the round; Engine Ventures, GHIC, and SiteGround joined as investors. This mix underscores a blend of biopharma-focused and growth-oriented capital backing Terrestrial Bio’s pivot. The company’s leadership credits this support as a catalyst for accelerating clinical development and manufacturing scale. A companion note from RA Capital’s communications channels corroborates the investor participation and the strategic intent behind the funding. See the RA Capital post for reader-accessible confirmation of the round’s composition. >.

Strategic Rebrand and Facility Plans

• Rebrand rationale and program focus: The company’s rebrand to Terrestrial Bio reflects a strategic shift toward therapies and patient-centered delivery, with GLP-1 as the initial focus. The press release describes a broader ambition to transform how therapies are delivered, stored, and accessed, moving away from traditional syringe-based administration and refrigeration dependencies. This change aligns with ongoing industry interest in more convenient, patch-based delivery systems for biologics and peptides. The press release includes a direct quote from CEO Rachel Sha explaining the branding rationale and the user-centric delivery vision. >.

• Facility expansion and timeline: The release confirms a lease with King Street Properties for a new manufacturing facility at Allston Labworks in Boston, spanning more than 40,000 square feet. The plan is to scale automated production to support late-stage development and early commercialization, with initial manufacturing activities expected to ramp in 2026. This element positions Terrestrial Bio to move from pilot-scale to a larger, more automated manufacturing footprint as it advances through regulatory pathways and clinical milestones. >.

Section 2: Why It Matters

GLP-1 Delivery and Patient Experience

• The strategic pivot to GLP-1 delivery via a patch addresses a historically challenging space in chronic therapies: patient adherence and administration burden. Terrestrial Bio’s MAP platform is designed to deliver biologics through a self-administered, temperature-stable format that eliminates sharps and refrigeration. The company’s leadership emphasizes that the patch approach could improve adherence by simplifying administration and reducing barrier costs for patients. A broader implication for the biotech industry is the potential to apply the MAP platform to a range of biologics beyond GLP-1, potentially expanding the addressable market for self-administered biologic therapies. The press release provides the core framing for this patient-centric value proposition. >.

Manufacturing Capacity as a Strategic Enabler

• By committing to a 40,000-square-foot manufacturing facility in Boston, Terrestrial Bio signals a move toward near-term ability to supply larger clinical and early commercial runs, reducing the gap between development and market entry. The Allston Labworks site is described as enabling automated line capabilities that could scale to multi-million unit outputs, subject to regulatory and clinical milestones. This facility expansion is a critical lever for the company’s go-to-market strategy and for validating its cost-structure advantages compared with traditional autoinjectors and cold-chain-dependent delivery methods. >.

Regulatory Pathways and Competitive Context

• The company’s strategy leverages a regulatory pathway that can be efficient for patch-based platforms delivering well-studied molecules. Engine Ventures has highlighted in its materials that, given semaglutide’s established safety profile, Terrestrial Bio can pursue a 505(b)(2) pathway to focus on delivery equivalence rather than duplicating large-scale trials. While this is not a guarantee of regulatory success, the framing suggests a more streamlined route than a full development program would entail for a novel biologic. This regulatory angle is a key dimension of the Series C funding rationale, as it informs both the timeline and risk profile for the company’s clinical development plan. >.

Investor Confidence and Strategic Implications

• The combination of a $50 million Series C led by a dedicated life sciences investor (RA Capital) with participation from strategic and growth investors underscores confidence in Terrestrial Bio’s platform and management team. The investor mix—centered on biopharma expertise and manufacturing-scale capabilities—signals expectations that the company will translate its MAP technology into clinically meaningful outcomes, while simultaneously building a robust manufacturing pipeline to support later-stage trials and potential commercialization. The RA Capital communications channel provides additional confirmation of investor involvement and strategic alignment with Terrestrial Bio’s mission. >.

Section 3: What’s Next

Clinical and Regulatory Milestones

• With the Series C financing in place, Terrestrial Bio is positioned to advance its lead GLP-1 program through Phase 1 and toward mid-stage clinical readouts, with initial clinical data anticipated in the near term. The press release frames a timeline that anticipates clinical progress within the year following the funding announcement, aligning with typical biotech development cadences for early-phase programs. The 505(b)(2) regulatory approach discussed in investor-facing materials may influence trial design and regulatory interactions, particularly as it pertains to demonstrating delivery parity and safety in patch-based administration. As the company proceeds, readers should monitor updates from Terrestrial Bio and investor communications for new clinical milestones and regulatory milestones. >.

Manufacturing and Commercial Readiness

• The 40,000-square-foot Allston Labworks facility sets the stage for a stepped manufacturing upgrade, from pilot-scale to scalable, automated production. This expansion, if realized in line with the company’s stated schedule, could reduce time-to-market pressure, support quality control at scale, and improve cost-per-dose economics. The facility’s development will be a critical signal of the company’s ability to meet the demand for GLP-1 patches if trials prove successful and regulatory approvals are secured. Watch for progress updates on equipment installation, automation milestones, and near-term production capacity metrics. >.

Near-Term Watch List

• Key milestones to watch include: (1) Phase 1 initiation and data readouts for the lead GLP-1 program, (2) regulatory interactions or submissions under the 505(b)(2) framework, (3) progress on the Allston Labworks facility build-out, including equipment commissioning and first large-scale batches, and (4) additional strategic investor updates or partnerships that could influence the company’s manufacturing strategy or go-to-market plans. Terrestrial Bio’s official statements and investor communications will be the primary sources to track these developments, with major updates likely to be issued through both the company’s news page and investor channels. >.

Closing

As of October 24, 2026, Terrestrial Bio’s progression from a needle-free patch developer to a clinically ambitious, manufacturing-capable company illustrates a broader trend in biotech: the convergence of platform technology with scalable production, aimed at improving patient experience and access to high-value therapies. The $50 million Series C funding on March 26, 2026, marks a formal inflection point that publicly pairs a rebranding effort with a strategic expansion into Boston’s manufacturing ecosystem, a move designed to translate early-stage clinical potential into tangible patient outcomes. The company’s leadership and investors position Terrestrial Bio to push the boundaries of how biologics can be delivered, potentially reshaping the economics and logistics of GLP-1 therapies as well as other biologics in the MAP platform. Readers should stay attuned to the company’s press releases and investor updates for new data, milestones, and partnership announcements that will define Terrestrial Bio’s trajectory in the coming quarters.

For ongoing coverage, Daily Bostonian will continue to monitor Terrestrial Bio’s clinical progress, manufacturing milestones, and strategic communications as the company advances toward its stated clinical and commercial objectives.